EA029941B1 - Фармацевтическая композиция на основе кристаллической формы ингибитора metap-2 и способ лечения ожирения - Google Patents
Фармацевтическая композиция на основе кристаллической формы ингибитора metap-2 и способ лечения ожирения Download PDFInfo
- Publication number
- EA029941B1 EA029941B1 EA201390675A EA201390675A EA029941B1 EA 029941 B1 EA029941 B1 EA 029941B1 EA 201390675 A EA201390675 A EA 201390675A EA 201390675 A EA201390675 A EA 201390675A EA 029941 B1 EA029941 B1 EA 029941B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dimethylaminoethoxy
- crystalline form
- fumagillol
- cinnamoyl
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/32—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41165510P | 2010-11-09 | 2010-11-09 | |
| PCT/US2011/059966 WO2012064838A1 (en) | 2010-11-09 | 2011-11-09 | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201390675A1 EA201390675A1 (ru) | 2013-08-30 |
| EA029941B1 true EA029941B1 (ru) | 2018-06-29 |
Family
ID=45048246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390675A EA029941B1 (ru) | 2010-11-09 | 2011-11-09 | Фармацевтическая композиция на основе кристаллической формы ингибитора metap-2 и способ лечения ожирения |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8349891B2 (https=) |
| EP (1) | EP2638023B1 (https=) |
| JP (1) | JP6239977B2 (https=) |
| KR (1) | KR101892768B1 (https=) |
| CN (2) | CN103347870A (https=) |
| AU (1) | AU2011326566B2 (https=) |
| BR (1) | BR112013011550A2 (https=) |
| CA (1) | CA2817199C (https=) |
| EA (1) | EA029941B1 (https=) |
| ES (1) | ES2610216T3 (https=) |
| IL (1) | IL226238B (https=) |
| MX (1) | MX2013005208A (https=) |
| MY (1) | MY177039A (https=) |
| NZ (1) | NZ610569A (https=) |
| PH (1) | PH12013500934A1 (https=) |
| SG (1) | SG190688A1 (https=) |
| UA (1) | UA111479C2 (https=) |
| WO (1) | WO2012064838A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8865746B2 (en) * | 2008-07-18 | 2014-10-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
| CA2777108A1 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| BR112012016793A2 (pt) | 2010-01-08 | 2018-07-31 | Zafgen Corp | compostos tipo fumagilol e métodos de fazer e usar os mesmos |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| CN103249735B (zh) | 2010-07-22 | 2016-04-06 | 扎夫根股份有限公司 | 三环化合物及其制备和使用方法 |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| US9173865B2 (en) | 2010-11-29 | 2015-11-03 | Zafgen, Inc. | Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol |
| MX344238B (es) | 2011-01-26 | 2016-12-07 | Zafgen Inc | Compuestos de tetrazol y métodos para preparar y usar los mismos. |
| EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| CN103764641B (zh) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | 部分饱和的三环化合物及其制备和使用方法 |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| JP2015509102A (ja) | 2012-01-18 | 2015-03-26 | ザフゲン，インコーポレイテッド | 三環式スルホン化合物並びにその作製および使用方法 |
| MX2014008706A (es) | 2012-01-18 | 2015-03-05 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
| BR112014027808A2 (pt) | 2012-05-07 | 2017-06-27 | Zafgen Inc | sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo |
| MX2014013599A (es) | 2012-05-08 | 2015-05-11 | Zafgen Inc | Tratamiento de la obesidad hipotalamica con inhibidores de metap2. |
| BR112014027981A2 (pt) | 2012-05-09 | 2017-06-27 | Zafgen Inc | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos |
| AU2013337282A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| MX2015005733A (es) | 2012-11-05 | 2016-02-10 | Zafgen Inc | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |
| US20150361139A1 (en) * | 2013-01-30 | 2015-12-17 | Sandoz Ag | Crystalline form of linaclotide |
| SI2958916T1 (sl) * | 2013-02-21 | 2018-11-30 | Pfizer Inc. | Trdne oblike selektivnih zaviralcev CDK4/6 |
| CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
| CN105431426A (zh) | 2013-04-10 | 2016-03-23 | 新德发制药有限公司 | Metap2抑制剂和治疗肥胖症的方法 |
| AR101608A1 (es) * | 2014-08-22 | 2016-12-28 | Zafgen Inc | Formulaciones que contienen un inhibidor de metap-2 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| US9969722B2 (en) | 2015-12-10 | 2018-05-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CN108697807B (zh) * | 2016-01-11 | 2021-11-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
| CN113453721B (zh) | 2018-10-26 | 2025-09-16 | 辛德弗雷克斯公司 | Metap2抑制剂的生物标志物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999059986A1 (en) * | 1998-05-15 | 1999-11-25 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives and processes for preparing the same |
| WO2005082349A1 (en) * | 2004-02-28 | 2005-09-09 | Chong Kun Dang Pharmaceutical Corp. | Composition for the treatment of obesity comprising fumagillol derivative |
| WO2010065883A2 (en) * | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| KR0138530B1 (ko) | 1988-09-01 | 1998-05-15 | 우메모또 요시마사 | 푸마길롤 유도체 |
| US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
| DE69001187T2 (de) | 1989-03-06 | 1993-07-08 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
| US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| TW282399B (https=) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| ATE205092T1 (de) | 1992-01-30 | 2001-09-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe |
| EP0602586B1 (en) | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
| US5900431A (en) | 1995-03-27 | 1999-05-04 | Sanofi | Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections |
| CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
| EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| AU3968597A (en) | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| WO1998056372A1 (en) | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| US6306819B1 (en) | 1997-10-31 | 2001-10-23 | Massachusetts Institute Of Technology | Method for regulating size of vascularized normal tissue |
| KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| EP1177176B1 (en) | 1999-04-28 | 2006-04-19 | Aventis Pharma Deutschland GmbH | Tri-aryl acid derivatives as ppar receptor ligands |
| US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| BR0115109A (pt) | 2000-11-01 | 2005-10-18 | Praecis Pharm Inc | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| EP1436286B1 (en) | 2001-09-27 | 2009-08-19 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
| US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| WO2005066197A2 (en) | 2003-12-29 | 2005-07-21 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| CN101142210A (zh) * | 2005-01-26 | 2008-03-12 | 株式会社钟根堂 | 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物 |
| FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| US20070078172A1 (en) | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| EP2217283A2 (en) | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US20120010290A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| CA2777108A1 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
-
2010
- 2010-11-09 PH PH1/2013/500934A patent/PH12013500934A1/en unknown
-
2011
- 2011-11-09 CN CN2011800600503A patent/CN103347870A/zh active Pending
- 2011-11-09 BR BR112013011550A patent/BR112013011550A2/pt not_active Application Discontinuation
- 2011-11-09 JP JP2013538848A patent/JP6239977B2/ja not_active Expired - Fee Related
- 2011-11-09 CA CA2817199A patent/CA2817199C/en not_active Expired - Fee Related
- 2011-11-09 WO PCT/US2011/059966 patent/WO2012064838A1/en not_active Ceased
- 2011-11-09 MX MX2013005208A patent/MX2013005208A/es active IP Right Grant
- 2011-11-09 EP EP11788684.6A patent/EP2638023B1/en active Active
- 2011-11-09 NZ NZ610569A patent/NZ610569A/en not_active IP Right Cessation
- 2011-11-09 SG SG2013035225A patent/SG190688A1/en unknown
- 2011-11-09 AU AU2011326566A patent/AU2011326566B2/en not_active Ceased
- 2011-11-09 UA UAA201307189A patent/UA111479C2/uk unknown
- 2011-11-09 KR KR1020137014698A patent/KR101892768B1/ko not_active Expired - Fee Related
- 2011-11-09 MY MYPI2013001644A patent/MY177039A/en unknown
- 2011-11-09 CN CN201710158431.4A patent/CN106905267A/zh active Pending
- 2011-11-09 ES ES11788684.6T patent/ES2610216T3/es active Active
- 2011-11-09 EA EA201390675A patent/EA029941B1/ru not_active IP Right Cessation
-
2012
- 2012-08-07 US US13/568,476 patent/US8349891B2/en not_active Expired - Fee Related
- 2012-11-16 US US13/679,310 patent/US8735447B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 IL IL226238A patent/IL226238B/en active IP Right Grant
-
2014
- 2014-02-12 US US14/178,788 patent/US9371312B2/en not_active Expired - Fee Related
-
2016
- 2016-05-03 US US15/145,403 patent/US9827221B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999059986A1 (en) * | 1998-05-15 | 1999-11-25 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives and processes for preparing the same |
| WO2005082349A1 (en) * | 2004-02-28 | 2005-09-09 | Chong Kun Dang Pharmaceutical Corp. | Composition for the treatment of obesity comprising fumagillol derivative |
| WO2010065883A2 (en) * | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
Non-Patent Citations (1)
| Title |
|---|
| YOO MEE KIM, JUAN JI AN, YONG-JUN JIN, YUMIE RHEE, BONG SOO CHA, HYUN CHUL LEE, AND SUNG-KIL LIM: "Assessment of the ant-obesity effects of the TNP-470 analog, CKD-732", JOURNAL OF MOLECULAR ENDOCRINOLOGY., SOCIETY FOR ENDOCRINOLOGY, GB, vol. 38, no. 4, 1 April 2007 (2007-04-01), GB, pages 455 - 465, XP002632891, ISSN: 0952-5041, DOI: 10.1677/jme.1.02165 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US8735447B2 (en) | 2014-05-27 |
| PH12013500934A1 (en) | 2022-10-24 |
| US20130197078A1 (en) | 2013-08-01 |
| AU2011326566B2 (en) | 2016-12-01 |
| KR101892768B1 (ko) | 2018-08-28 |
| JP6239977B2 (ja) | 2017-11-29 |
| IL226238A0 (en) | 2013-07-31 |
| CA2817199C (en) | 2019-01-15 |
| CN106905267A (zh) | 2017-06-30 |
| MY177039A (en) | 2020-09-03 |
| US20170087119A1 (en) | 2017-03-30 |
| EP2638023B1 (en) | 2016-09-07 |
| US9827221B2 (en) | 2017-11-28 |
| MX2013005208A (es) | 2013-08-01 |
| US9371312B2 (en) | 2016-06-21 |
| WO2012064838A1 (en) | 2012-05-18 |
| SG190688A1 (en) | 2013-07-31 |
| ES2610216T3 (es) | 2017-04-26 |
| AU2011326566A1 (en) | 2013-05-30 |
| EP2638023A1 (en) | 2013-09-18 |
| US8349891B2 (en) | 2013-01-08 |
| US20150018413A1 (en) | 2015-01-15 |
| KR20140009994A (ko) | 2014-01-23 |
| CA2817199A1 (en) | 2012-05-18 |
| UA111479C2 (uk) | 2016-05-10 |
| US20120316233A1 (en) | 2012-12-13 |
| BR112013011550A2 (pt) | 2017-10-24 |
| NZ610569A (en) | 2015-06-26 |
| EA201390675A1 (ru) | 2013-08-30 |
| JP2013543867A (ja) | 2013-12-09 |
| IL226238B (en) | 2019-02-28 |
| CN103347870A (zh) | 2013-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA029941B1 (ru) | Фармацевтическая композиция на основе кристаллической формы ингибитора metap-2 и способ лечения ожирения | |
| EP3710465B1 (en) | Salts and crystal forms of gabaa positive allosteric modulator | |
| JP7845821B2 (ja) | 化合物の結晶形態及び化合物の結晶形態を生成する方法 | |
| US9260419B2 (en) | Polymorphic salt of a metap-2 inhibitor and methods of making and using same | |
| KR20230054373A (ko) | 결정질 ppar-델타 작용제 | |
| KR20200074169A (ko) | 4-(4-(1-이소프로필-7-옥소-1,4,6,7-테트라히드로스피로[인다졸-5,4'-피페리딘]-1'-카르보닐)-6-메톡시피리딘-2-일)벤조산의 결정질 2-아미노-2-(히드록시메틸)프로판-1,3-디올 염 | |
| RU2537847C2 (ru) | Новые фумаратные соли антагониста гистаминового рецептора н3 | |
| US12129261B2 (en) | Crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them | |
| CN116768909B (zh) | Vanin酶抑制剂的盐型、晶型及其制备方法和应用 | |
| CA3231117A1 (en) | Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases | |
| RU2844681C2 (ru) | Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции | |
| US20220372006A1 (en) | Solid state forms of pemafibrate | |
| HK1189878B (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same | |
| WO2026024591A1 (en) | Tryptamine prodrug solid forms | |
| EP4646408A1 (en) | Crystalline form of an n-heteroarylsulphonamide, compositions and methods thereof | |
| JP2024532601A (ja) | インドール化合物の固体形態、その調製方法及びその使用 | |
| TW200302830A (en) | Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate | |
| HK40037178A (en) | Salts and crystal forms of gabaa positive allosteric modulator | |
| HK40037178B (en) | Salts and crystal forms of gabaa positive allosteric modulator | |
| TW201026670A (en) | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |